Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ETX101
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Encoded Updates on ETX101 for Dravet, Highlights 2024 Wins, Shares 2025 Plan
Details : ETX101 is an AAV9-mediated gene regulation therapy designed to upregulate expression of the SCN1A gene in GABAergic inhibitory interneurons. It is being evaluated for the treatment of Dravet syndrome.
Product Name : ETX101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 13, 2025
Lead Product(s) : ETX101
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ETX101
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Encoded Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101
Details : ETX101, an AAV9-mediated gene therapy, selectively upregulates SCN1A gene expression in GABAergic neurons. It is being studied for treating SCN1A-positive Dravet syndrome in young children.
Product Name : ETX101
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
February 26, 2024
Lead Product(s) : ETX101
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ETX101
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Encoded Receives US IND Clearance and Australian Approval for ETX101
Details : ETX101 is an AAV9-mediated gene therapy designed to upregulate SCN1A expression in GABAergic neurons, currently evaluated in phase 1/2 trials for SCN1A-positive Dravet syndrome.
Product Name : ETX101
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
February 06, 2024
Lead Product(s) : ETX101
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Multiple adaptable DNA sequence-encoded human genetic elements are modality-agnostic and can be combined to customize expression profiles to optimize therapeutic approaches in and beyond the brain.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 18, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ETX101
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : GV
Deal Size : Undisclosed
Deal Type : Series D Financing
Details : ETX101, Encoded's lead asset, was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by FDA for the treatment of SCN1A+ Dravet Syndrome.
Product Name : ETX101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 22, 2020
Lead Product(s) : ETX101
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : GV
Deal Size : Undisclosed
Deal Type : Series D Financing
Lead Product(s) : ETX101
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gene Therapy Shows Promise in Mouse Model of Dravet Syndrome
Details : ETX101, a gene therapy developed by Encoded Therapeutics to restore the levels of NaV1.1-alpha specifically in GABAergic neurons, is currently progressing toward clinical development for SCN1A-positive Dravet patients.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 19, 2020
Lead Product(s) : ETX101
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable